Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New technique uses your own skin to prevent sagging after breast reduction

NCT ID NCT07657962

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This study looks at whether using a small piece of a woman's own skin as a support during breast reduction surgery can help prevent the breast from sagging again. 70 women having the surgery will be split into two groups: one gets the extra skin support, the other does not. Researchers will measure breast shape changes over 6 months to see if the skin graft makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous free dermal graft (patient's own skin used as a support during surgery)
What this could lead to
If successful, this technique could help women who have breast reduction surgery maintain a better breast shape for longer, reducing the chance of sagging.
What could go wrong
This is a small, early observational study, not a randomized trial. The graft may not prevent sagging, and results may not apply to all patients. There are standard surgical risks like infection or poor healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of female patients aged 18 to 65 years who are scheduled to undergo primary bilateral reduction mammaplasty using the superior pedicle vertical scar technique at the Department of Plastic, Reconstructive and Aesthetic Surgery, Sivas Cumhuriyet University. Eligible patients will be evaluated consecutively during the recruitment period. Patients who meet the eligibility criteria and provide written informed consent for clinical measurements, standardized medical photography, and postoperative follow-up will be included.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 65 years * Planned primary bilateral reduction mammaplasty * Planned use of the superior pedicle vertical scar technique * Willingness to attend at least 6 months of postoperative follow-up * Ability to provide written informed consent * Consent for standardized medical photography and clinical breast measurements Exclusion Criteria: * Previous breast surgery * Oncoplastic breast reduction * Unilateral reduction mammaplasty * Use of a pedicle technique other than the superior pedicle * Use of a scar pattern other than the vertical scar pattern * Presence of a systemic condition expected to significantly impair wound healing * Active smoking within the last 6 weeks before surgery * Incomplete 6-month follow-up data for the primary outcome analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast hypertrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sivas Cumhuriyet University

    RECRUITING

    Sivas, Sivas, 58050, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.